Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 16/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 3/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587639 | 0.89 | CXCR3 (0.47) | CXCR3KCNH2 | |
| SCHEMBL13031426 | 0.87 | CXCR3 (0.40) | CXCR3KCNH2RXFP1 | |
| SCHEMBL3581779 | 0.85 | TLR9 (0.34) | KCNH2CPT1ACPT2CPT1B | |
| SCHEMBL3584282 | 0.84 | KCNH2 (0.34) | KCNH2CPT1ACPT2CPT1B | |
| Hydrochloric Acid SCHEMBL3588301 | 0.83 | CPT1A (0.34) | CPT1ACPT2CPT1B | |
| SCHEMBL3588046 | 0.83 | ALK (0.34) | CPT1ACPT2 | |
| SCHEMBL3589593 | 0.82 | LMNA (0.40) | CXCR3KCNH2CPT1ACPT2 | |
| SCHEMBL3592264 | 0.82 | CPT1A (0.33) | CPT1ACPT2CPT1B | |
| SCHEMBL3593480 | 0.82 | CPT1A (0.35) | KCNH2CPT1ACPT2CPT1B | |
| SCHEMBL3581098 | 0.82 | CPT1A (0.33) | CPT1ACPT2CPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | CXCR3 1/4885KCNH2 2030/4885RXFP1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.